← Eichor
Study identifier: NCT07115628 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Accelerated TMS for Treatment-Resistant ECT

Condition: Major Depressive Disorder (MDD)  ·  Sponsor: Universitair Ziekenhuis Brussel

PhaseNA
Planned participants200
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study investigates whether an additional treatment using transcranial magnetic stimulation (TMS) can help severely depressed patients who did not respond well to electroconvulsive therapy (ECT). All participants will first receive standard ECT treatment for depression, including brain scans (fMRI), psychological testing, clinical assessments, and the collection of blood and stool samples. If the ECT treatment is not effective, patients will be invited to participate in a second part of the study where they receive a 4-day course of accelerated TMS (20 sessions in total). The study aims to assess whether this additional TMS treatment can reduce depressive symptoms. The study also explores how brain structure, genetics, and gut health may relate to treatment success. In total, 200 patients will be included.

This description comes directly from the study's public registry record.

Talk to the study team

Chris Baeken, MD, PhD  ·  +32 2 477 6801  ·  chris.baeken@uzbrussel.be

Always discuss trial participation with your own doctor first.

Locations (1)

UZ BrusselJette, Brussels Capital, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07115628